Kim LHY, Saleh C, Whalen-Browne A, et al. - Via this systematic review and meta-analysis, researchers assessed outcomes and adverse events related to triple therapy [inhaled corticosteroids (ICS), long-acting β ₂ -agonists (LABAs), and long-acting muscarinic antagonists] vs dual therapy [ICS plus LABA] among children and adults suffering from persistent uncontrolled asthma. They explored MEDLINE, Embase, CENTRAL, ICTRP, FDA, and EMA databases to identify randomized clinical trials comparing triple vs dual therapy in patients experiencing moderate to severe asthma. They analyzed 20 randomized clinical trials with 11,894 patients. Findings revealed a significant link of triple therapy with fewer severe asthma exacerbations as well as with modest improvements in asthma control without significant differences in quality of life or mortality when compared with dual therapy in children (aged 6 to 18 years) and adults experiencing moderate to severe asthma.